NEWS RELEASE

Print Page
<< Back

Mannatech Announces Issuance of New Patent
Patent Granted for Technology Related to PhytoMatrix Caplets and PhytoBurst Nutritional Chews

COPPELL, Texas, Aug 19, 2010 (BUSINESS WIRE) --

Mannatech, Incorporated(NASDAQ: MTEX), a global pioneer in the development of high-quality health, weight and fitness and skin care solutions based on nutritional science, announced today the Republic of South Africa Patent Office has granted the company patent number 2008/07423 entitled "All Natural Multivitamin and Multimineral Dietary Supplement Formulations for Enhanced Absorption and Biological Utilization" for technology related to its PhytoMatrix(R) caplets and PhytoBurst(R) nutritional chews products.

"The issuance of this new patent extends protection to our research and development of technology related to our PhytoMatrix caplets and PhytoBurst nutritional chews products and is an important addition to our current intellectual property portfolio," said Robert A. Sinnott, Ph.D., MNS, co-CEO and chief science officer of Mannatech. "This is the first patent for technology related to these specific products and we will continue to protect this technology in other parts of the world."

Mannatech currently holds 61 patents in 31 countries for its health-related technologies.

Many of Mannatech's products are based on Real Food TechnologySM solutions, which provide consumers with products that contain standardized levels of natural and plant-sourced nutrients. Food-sourced ingredients are chosen from those scientifically proven to most benefit the human body.

Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at mannatech.com.

About Mannatech

Mannatech, Incorporated, develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. These proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore and the Republic of Korea. For more information, visit mannatech.com.

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

SOURCE: Mannatech, Incorporated

Mannatech, Incorporated
Allison Lowe, 972-499-6631
Allison.Lowe@hck2.com